Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,228 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,228 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00301379 | Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients | — | terminated | Mar 10, 2006 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and… | Phase 1 | withdrawn | Jun 24, 2022 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell… | Phase 2 | withdrawn | Jun 9, 2022 | Ellipses Pharma | Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies… | Efficacy / futility |
| NCT04348916 | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With… | Phase 1 | terminated | Apr 16, 2020 | Oncorus, Inc. | Terminated due to Oncorus portfolio reprioritization | Sponsor / business decision |
| NCT05564338 | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus… | Phase 3 | withdrawn | Oct 3, 2022 | BeiGene | Study has voluntarily discontinued due to a change in the company-level development strategy and is… | Safety / toxicity |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT04193904 | A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in… | Phase 1 | terminated | Dec 10, 2019 | 4D pharma plc | Sponsor insolvency | Other (stated, no rule matched) |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | Phase 2 | withdrawn | Jun 2, 2023 | Shi Ming | Protocol adjustment | Other (stated, no rule matched) |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma… | Phase 1 | terminated | May 16, 2022 | Codiak BioSciences | Company Bankruptcy | Sponsor / business decision |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated… | Phase 1 / Phase 2 | terminated | Jul 31, 2017 | National Cancer Institute (NCI) | Study terminated due to drug supply issues. | Drug supply |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating… | Phase 1 / Phase 2 | withdrawn | Jan 26, 2015 | Eastern Cooperative Oncology Group | The study did not open to accrual. No start date and no completion dates. | Enrollment / accrual |
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced… | Phase 3 | terminated | Nov 15, 2019 | NuCana plc | A pre-planned futility analysis concluded that NUC-1031 plus cisplatin was unlikely to achieve its… | Efficacy / futility |
| NCT05039736 | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR… | Phase 2 | withdrawn | Sep 10, 2021 | M.D. Anderson Cancer Center | 0 participants accrued | Enrollment / accrual |
| NCT04535492 | Technology-Based Cancer Screening Intervention | N/A | withdrawn | Sep 2, 2020 | Medical University of South Carolina | No further funding | Funding |
| NCT05251038 | Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | Phase 1 / Phase 2 | withdrawn | Feb 22, 2022 | Devalingam Mahalingam | Funder Decision | Other (stated, no rule matched) |
| NCT03385343 | Staging of Superficial EAC Using VLE | N/A | terminated | Dec 28, 2017 | Mayo Clinic | Device company went out of business | Sponsor / business decision |
| NCT02489214 | Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer | Phase 1 / Phase 2 | terminated | Jul 2, 2015 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | Phase 4 | withdrawn | Jun 25, 2014 | Tokyo Medical and Dental University | I retired my post before enrollment | Enrollment / accrual |
| NCT03662841 | Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma | N/A | terminated | Sep 10, 2018 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT03808766 | A Study on the Angioarchitecture of Hepatocellular Carcinoma | N/A | terminated | Jan 18, 2019 | Chinese University of Hong Kong | Poor patient accrual | Enrollment / accrual |
| NCT05249569 | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Feb 21, 2022 | University of Texas Southwestern Medical Center | Sponsor pulled support for one of the study drugs. | Other (stated, no rule matched) |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT02682485 | Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of…(SES-DTA) | Phase 2 | withdrawn | Feb 15, 2016 | University of Chicago | Lack of funding | Funding |
| NCT05246943 | The Correlation of a D-dimer Testing Protocol With Venous Thromboembolism in Surgical… | — | withdrawn | Feb 18, 2022 | The University of Texas Medical Branch, Galveston | No participants enrolled. | Enrollment / accrual |
| NCT01160926 | Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial(DREAMtherapy) | Phase 1 | terminated | Jul 13, 2010 | The Christie NHS Foundation Trust | 2 DLTs had been reported from first 4 patients on lowest possible dose cohort. | Other (stated, no rule matched) |
| NCT03118349 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking… | Phase 1 | terminated | Apr 18, 2017 | BioNTech Research & Development, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04696848 | The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid… | Phase 1 / Phase 2 | terminated | Jan 6, 2021 | Tae Won Kim | Recruitment difficulty | Enrollment / accrual |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT03790111 | A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With…(TELE-ABC) | Phase 2 | terminated | Dec 31, 2018 | TerSera Therapeutics LLC | Did not meet pre-specified Progression-Free Survival at Month 6 for Stage 2 Analysis | Other (stated, no rule matched) |
| NCT04882423 | Vegetable Intake Effect on Heterocyclic Amine Metabolism | N/A | terminated | May 12, 2021 | Masonic Cancer Center, University of Minnesota | PI left the university | Investigator |
| NCT05158907 | Patient Reported Scale vs CTCAE Grading: A Prospective Comparator Study(PROSE) | N/A | suspended | Dec 15, 2021 | Tata Medical Center | Patient recruitment is slow | Enrollment / accrual |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | Phase 1 | withdrawn | Apr 21, 2021 | University of Oxford | Lack of recruitment | Enrollment / accrual |
| NCT04150874 | Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow… | Early Phase 1 | terminated | Nov 5, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual | Enrollment / accrual |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Phase 2 | terminated | Jun 22, 2020 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT05183295 | Medical Food for the Dietary Management of Metastatic Colorectal Cancer | N/A | withdrawn | Jan 10, 2022 | Faeth Therapeutics | Withdrawn by Sponsor. | Other (stated, no rule matched) |
| NCT03019588 | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian… | Phase 3 | terminated | Jan 12, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT00430313 | Effects of Acupoint Electro-stimulation on Preventing Nausea and Vomiting Induced by… | N/A | withdrawn | Feb 1, 2007 | M.D. Anderson Cancer Center | No participants enrolled | Enrollment / accrual |
| NCT04777708 | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | Early Phase 1 | terminated | Mar 2, 2021 | Jonsson Comprehensive Cancer Center | Withdrawn by sponsor | Other (stated, no rule matched) |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Phase 1 | terminated | Aug 2, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05157451 | Y-90 Versus SBRT for Inoperable HCC | Phase 2 | withdrawn | Dec 15, 2021 | OHSU Knight Cancer Institute | Not feasible at this time. | Other (stated, no rule matched) |
| NCT04635527 | A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE)… | Phase 1 | terminated | Nov 19, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue… | Sponsor / business decision |
| NCT03742596 | Effect of Probiotics Supplementation on the Side Effects of Radiation Therapy Among… | Phase 2 / Phase 3 | withdrawn | Nov 15, 2018 | King Hussein Cancer Center | This study was closed without recruitment | Enrollment / accrual |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT04649671 | The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With… | N/A | terminated | Dec 2, 2020 | Samsung Medical Center | Difficulty in recruitment and deficit of research fund | Enrollment / accrual |
| NCT01792882 | Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples(GBCPRT0008) | — | withdrawn | Feb 15, 2013 | Global BioClinical | not stated | Not stated |
| NCT05606081 | Predicting Risk for Post-polypectomy Colorectal Cancer(PREDICT) | N/A | withdrawn | Nov 4, 2022 | Kaiser Permanente | Alternative method of implementation, study not needed | Other (stated, no rule matched) |
| NCT05506800 | Guangzhou Women's Health Cohort Study (GWHCS) | — | suspended | Aug 18, 2022 | Guangzhou Women and Children's Medical Center | Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily. | COVID-19 / pandemic |
| NCT01239095 | Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing… | Phase 1 | terminated | Nov 11, 2010 | Richard Whelan | not stated | Not stated |
| NCT04177602 | Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer… | Phase 1 / Phase 2 | terminated | Nov 26, 2019 | Universitätsklinikum Hamburg-Eppendorf | Due to the amended therapy strategies for rectal cancer recently, it was decided not to transfer… | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jun 15, 2023source: clinicaltrials